Cytokinetics(CYTK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CYTK Cytokinetics

交易中 02-19 13:21:44 EST

67.02

+0.04

+0.06%

最高67.20	最低65.54	成交量37.43万
今开66.61	昨收66.98	日振幅2.48%
总市值81.94亿	流通市值79.81亿	总股本1.22亿
成交额2,489万	换手率0.31%	流通股本1.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CYTK","market":"US","secType":"STK","nameCN":"Cytokinetics","latestPrice":67.02,"timestamp":1771525301346,"preClose":66.98,"halted":0,"volume":374280,"delay":0,"changeRate":0.0005971931919974923,"floatShares":119088114,"shares":122264929,"eps":-6.317914,"marketStatus":"交易中","change":0.04,"latestTime":"02-19 13:21:44 EST","open":66.61,"high":67.2,"low":65.54,"amount":24885607.718399998,"amplitude":0.024784,"askPrice":67.02,"askSize":214,"bidPrice":66.95,"bidSize":14,"shortable":3,"etf":0,"ttmEps":-6.317914,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1771534800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1083211200000,"exchange":"NASDAQ","adjPreClose":66.98,"postHourTrading":{"tag":"盘后","latestPrice":66.98,"preClose":66.98,"latestTime":"17:28 EST","volume":27024,"amount":1810103.8801,"timestamp":1771453693501,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.371256,"impliedVol":0.7391,"impliedVolPercentile":0.5378},"requestUrl":"/m/hq/s/CYTK/tweets","defaultTab":"tweets","newsList":[{"id":"1180684705","title":"Cytokinetics宣布欧盟委员会批准Myqorzo®（Aficamten）用于治疗成人症状性梗阻性肥厚型心肌病","url":"https://stock-news.laohu8.com/highlight/detail?id=1180684705","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180684705?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:31","pubTimestamp":1771331475,"startTime":"0","endTime":"0","summary":"生物制药公司Cytokinetics宣布，其创新药物Myqorzo®（Aficamten）已获得欧盟委员会正式批准，适用于治疗成人症状性梗阻性肥厚型心肌病（HCM）。这一监管里程碑标志着该药物在欧洲市场取得重要进展，为患有此类心脏疾病的患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CYTK","BK4588","BK4505","BK4139"],"gpt_icon":0},{"id":"1136079223","title":"财报前瞻｜Cytokinetics本季营收或增296.84%，机构看多占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1136079223","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136079223?lang=zh_cn&edition=full","pubTime":"2026-02-17 11:07","pubTimestamp":1771297664,"startTime":"0","endTime":"0","summary":"Cytokinetics将于2026年02月24日盘后公布最新季度业绩，市场普遍关注收入弹性与费用节奏下的盈利路径变化。基于市场一致预期，本季度Cytokinetics营收预计为691.13万美元，同比变动+296.84%；调整后每股收益预计为-1.46美元，同比变动-22.08%，息税前利润预计为-1.77亿美元，同比变动-25.66%；上季度财报未见对本季度毛利率、净利润或净利率的可量化指引，当前一致预期未显示相关数据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Cytokinetics本季营收或增296.84%，机构看多占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK"],"gpt_icon":0},{"id":"1164613916","title":"Cytokinetics携手奥运冠军Sydney McLaughlin-Levrone 共同提升对肥厚型心肌病整体影响的认识","url":"https://stock-news.laohu8.com/highlight/detail?id=1164613916","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164613916?lang=zh_cn&edition=full","pubTime":"2026-01-27 21:01","pubTimestamp":1769518880,"startTime":"0","endTime":"0","summary":"生物制药企业Cytokinetics与奥运金牌得主Sydney McLaughlin-Levrone展开合作，旨在提高公众对肥厚型心肌病全方位影响的认识。此次合作将聚焦于揭示该疾病对患者生理、心理及生活质量的综合影响，打破仅关注单一症状的传统认知局限。作为拥有深厚心血管疾病研究背景的公司，Cytokinetics长期致力于创新疗法的开发。随着公众对HCM认知边界的拓展，未来有望推动更人性化的医疗方案诞生。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CYTK","BK4585","BK4588","BK4505"],"gpt_icon":0},{"id":"1162316069","title":"Cytokinetics宣布Myqorzo™（Aficamten）在美国上市，用于治疗成人症状性梗阻性肥厚型心肌病以改善功能能力和症状","url":"https://stock-news.laohu8.com/highlight/detail?id=1162316069","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162316069?lang=zh_cn&edition=full","pubTime":"2026-01-27 20:32","pubTimestamp":1769517123,"startTime":"0","endTime":"0","summary":"Cytokinetics公司宣布，其创新药物Myqorzo™（Aficamten）现已在美国市场正式推出。该药物专为成人症状性梗阻性肥厚型心肌病（HCM）患者设计，旨在显著提升患者的功能能力并有效缓解相关症状。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK","BK4505","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2593243985","title":"美股异动 | 阿夫凯泰片获批准上市 Cytokinetics(CYTK.US)大涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593243985","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593243985?lang=zh_cn&edition=full","pubTime":"2025-12-22 23:45","pubTimestamp":1766418320,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，Cytokinetics(CYTK.US)大涨超10%，续创年内新高，现报69.34美元。消息面上，近日，国家药品监督管理局通过优先审评审批程序，批准Cytokinetics, Incorporated申报的1类创新药阿夫凯泰片(商品名：星舒平)上市，该药用于治疗纽约心脏协会(NYHA)心功能分级II-III级的梗阻性肥厚型心肌病(HCM)成人患者，以改善运动能力和症状。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | 阿夫凯泰片获批准上市 Cytokinetics(CYTK.US)大涨超10%","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","CYTK","BK4588","BK4139","BK4505"],"gpt_icon":0},{"id":"1124007868","title":"Cytokinetics宣布Myqorzo™（Aficamten）获得FDA批准，用于治疗有症状的梗阻性肥厚型心肌病，以改善功能能力和症状","url":"https://stock-news.laohu8.com/highlight/detail?id=1124007868","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124007868?lang=zh_cn&edition=full","pubTime":"2025-12-20 05:00","pubTimestamp":1766178019,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布Myqorzo™（Aficamten）获得FDA批准，用于治疗有症状的梗阻性肥厚型心肌病，以改善功能能力和症状。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","BK4505","CYTK"],"gpt_icon":0},{"id":"1146256720","title":"Cytokinetics宣布Myqorzo®（Aficamten）在中国获得NMPA批准，用于治疗梗阻性肥厚型心肌病患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1146256720","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146256720?lang=zh_cn&edition=full","pubTime":"2025-12-17 20:30","pubTimestamp":1765974616,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布Myqorzo®（Aficamten）在中国获得NMPA批准，用于治疗梗阻性肥厚型心肌病患者","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BK4585","BK4588","CYTK"],"gpt_icon":0},{"id":"1117859396","title":"Cytokinetics宣布Myqorzo®（Aficamten）治疗阻塞性肥厚型心肌病获得积极的CHMP意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1117859396","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117859396?lang=zh_cn&edition=full","pubTime":"2025-12-12 21:45","pubTimestamp":1765547116,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布Myqorzo®（Aficamten）治疗阻塞性肥厚型心肌病获得积极的CHMP意见。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK","BK4588","BK4139","BK4505","BK4585"],"gpt_icon":0},{"id":"1156065229","title":"异动解读 | Cytokinetics股价盘中大涨5.03%，分析师上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1156065229","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156065229?lang=zh_cn&edition=full","pubTime":"2025-11-12 01:44","pubTimestamp":1762883080,"startTime":"0","endTime":"0","summary":"生物制药公司Cytokinetics（CYTK）今日表现强劲，盘中大涨5.03%，引发投资者关注。\n\n消息面上，加拿大皇家银行资本市场分析师对Cytokinetics股票做出了积极评价。该机构将Cytokinetics的目标价从82美元上调至87美元，显示出对公司未来发展前景的看好。这一利好消息可能是推动股价上涨的主要原因。\n\nCytokinetics是一家专注于开发肌肉生物学新疗法的生物制药公司。分析师目标价的上调可能反映了市场对公司在研产品管线和未来增长潜力的信心增强。投资者应密切关注公司未来的临床试验结果和产品开发进展，这些因素可能会进一步影响股价表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CYTK"],"gpt_icon":0},{"id":"1109773369","title":"Cytokinetics在2025年肥厚性心肌病医学会科学会议及美国心脏协会科学会议上发布Maple-HCM的新增数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1109773369","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109773369?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:32","pubTimestamp":1762777931,"startTime":"0","endTime":"0","summary":"Cytokinetics在2025年肥厚性心肌病医学会科学会议及美国心脏协会科学会议上发布Maple-HCM的新增数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","CYTK","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"1159228276","title":"Cytokinetics宣布将于2025年在肥厚型心肌病医学协会科学会议和美国心脏协会科学会议上进行多场演讲","url":"https://stock-news.laohu8.com/highlight/detail?id=1159228276","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159228276?lang=zh_cn&edition=full","pubTime":"2025-10-31 19:31","pubTimestamp":1761910297,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布将于2025年在肥厚型心肌病医学协会科学会议和美国心脏协会科学会议上进行多场演讲","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4505","CYTK","BK4139"],"gpt_icon":0},{"id":"2568496296","title":"Cytokinetics将发行可转换优先票据筹集最多5.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568496296","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568496296?lang=zh_cn&edition=full","pubTime":"2025-09-17 20:42","pubTimestamp":1758112920,"startTime":"0","endTime":"0","summary":"周三盘前，生物制药公司Cytokinetics（CYTK）上涨0.6%，此前该公司宣布，计划通过发行2031年到期的可转换优先票据筹集最多5.5亿美元资金。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-09-17/doc-infqvhrz2546128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4505","BK4585","BK4588","CYTK","BK4139"],"gpt_icon":0},{"id":"1181470114","title":"Cytokinetics宣布定价6.5亿美元扩大规模可转换优先票据发行；为2027年可转换票据部分进行再融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1181470114","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181470114?lang=zh_cn&edition=full","pubTime":"2025-09-17 11:46","pubTimestamp":1758080777,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布定价6.5亿美元扩大规模可转换优先票据发行；为2027年可转换票据部分进行再融资","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK","BK4505","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"1107967207","title":"Cytokinetics——若Aficamten获FDA批准，公司仍预期其将具备差异化标签和风险缓解特征——SEC文件显示","url":"https://stock-news.laohu8.com/highlight/detail?id=1107967207","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107967207?lang=zh_cn&edition=full","pubTime":"2025-09-17 04:13","pubTimestamp":1758053597,"startTime":"0","endTime":"0","summary":"Cytokinetics——若Aficamten获FDA批准，公司仍预期其将具备差异化标签和风险缓解特征——SEC文件显示","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","CYTK","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"1122526064","title":"Cytokinetics盘后股价下跌4.2%，宣布拟发行5.5亿美元可转换优先债券","url":"https://stock-news.laohu8.com/highlight/detail?id=1122526064","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122526064?lang=zh_cn&edition=full","pubTime":"2025-09-17 04:10","pubTimestamp":1758053451,"startTime":"0","endTime":"0","summary":"Cytokinetics盘后股价下跌4.2%，该公司宣布拟通过私募方式发行价值5.5亿美元的可转换优先债券。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4585","BK4588","CYTK","BK4139"],"gpt_icon":0},{"id":"2564388606","title":"百事涨5.8%激进投资机构Elliott Management已持有其40 亿美元股份。Cytokinetics涨27.","url":"https://stock-news.laohu8.com/highlight/detail?id=2564388606","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564388606?lang=zh_cn&edition=full","pubTime":"2025-09-02 21:30","pubTimestamp":1756819857,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0326950275.SGD","LU0173614495.USD","BK4139","LU0287142896.SGD","BK4526","LU0651946864.USD","LU0651947912.USD","LU1515016050.SGD","BK4079","BK4509","LU1688375341.USD","BK4585","BK4588","BK4504","LU0244354667.USD","BEKE","LU0359201885.HKD","LU1831875114.USD","LU0463099449.HKD","LU1051769294.HKD","CSTA.U","LU1051768304.USD","LU1023057109.AUD","LU0359201612.USD","BK4505","LU0359202008.SGD","CYTK","LU1188198961.HKD","BK4548"],"gpt_icon":0},{"id":"1141869495","title":"Cytokinetics公布Maple-HCM研究主要结果，在2025年欧洲心脏病学会大会发表并刊登于《新英格兰医学杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=1141869495","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141869495?lang=zh_cn&edition=full","pubTime":"2025-08-30 15:20","pubTimestamp":1756538435,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布了其Maple-HCM研究的主要结果，相关数据已在2025年欧洲心脏病学会大会上进行了展示，同时研究成果也已发表在权威医学期刊《新英格兰医学杂志》上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CYTK","BK4139","BK4505","BK4588"],"gpt_icon":0},{"id":"1100177896","title":"Cytokinetics：接受阿菲卡坦治疗的患者中51%在NYHA功能分级上有一个或多个等级改善，而接受美托洛尔治疗的患者仅为26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100177896","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100177896?lang=zh_cn&edition=full","pubTime":"2025-08-30 15:20","pubTimestamp":1756538430,"startTime":"0","endTime":"0","summary":"Cytokinetics：接受阿菲卡坦治疗的患者中51%在NYHA功能分级上有一个或多个等级改善，而接受美托洛尔治疗的患者仅为26%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","BK4505","CYTK"],"gpt_icon":0},{"id":"1116510698","title":"Cytokinetics：积极试验结果显示Aficamten优于标准治疗药物β受体阻滞剂美托洛尔","url":"https://stock-news.laohu8.com/highlight/detail?id=1116510698","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116510698?lang=zh_cn&edition=full","pubTime":"2025-08-30 15:20","pubTimestamp":1756538428,"startTime":"0","endTime":"0","summary":"Cytokinetics：积极试验结果显示Aficamten优于标准治疗药物β受体阻滞剂美托洛尔","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","BK4585","BK4139","CYTK"],"gpt_icon":0},{"id":"1167884525","title":"Cytokinetics：与美托洛尔相比，Aficamten使NT-proBNP降低81%并显著改善左心房容积指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1167884525","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167884525?lang=zh_cn&edition=full","pubTime":"2025-08-30 15:20","pubTimestamp":1756538421,"startTime":"0","endTime":"0","summary":"Cytokinetics公司宣布，与美托洛尔相比，其药物Aficamten能够使NT-proBNP水平降低81%，并在左心房容积指数方面实现显著改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","BK4505","CYTK"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cytokinetics.com","stockEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.0703},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.747},{"period":"1year","weight":0.4757},{"period":"ytd","weight":0.0541}],"compareEarnings":[{"period":"1week","weight":-0.0082},{"period":"1month","weight":-0.0078},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1223},{"period":"ytd","weight":0.0064}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cytokinetics, Incorporated于1997年8月5日成立，符合特拉华州的法律规定。它是一家处于临床阶段的生物制药公司，主要致力于为重大疾病和糟糕的医疗条件提供潜在的治疗方法的这样一种调节肌肉功能的新型小分子治疗方法的发现和发展。它目前处于发展阶段，着重于科研，开发药品筛选技术和融资。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.002159},{"month":2,"riseRate":0.5,"avgChangeRate":-0.020408},{"month":3,"riseRate":0.47619,"avgChangeRate":-0.003116},{"month":4,"riseRate":0.619048,"avgChangeRate":0.016608},{"month":5,"riseRate":0.590909,"avgChangeRate":0.01979},{"month":6,"riseRate":0.409091,"avgChangeRate":-0.000087},{"month":7,"riseRate":0.681818,"avgChangeRate":0.060358},{"month":8,"riseRate":0.636364,"avgChangeRate":0.040484},{"month":9,"riseRate":0.409091,"avgChangeRate":0.034179},{"month":10,"riseRate":0.318182,"avgChangeRate":-0.070805},{"month":11,"riseRate":0.5,"avgChangeRate":0.021311},{"month":12,"riseRate":0.454545,"avgChangeRate":0.096331}],"exchange":"NASDAQ","name":"Cytokinetics","nameEN":"Cytokinetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cytokinetics(CYTK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cytokinetics(CYTK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cytokinetics,CYTK,Cytokinetics股票,Cytokinetics股票老虎,Cytokinetics股票老虎国际,Cytokinetics行情,Cytokinetics股票行情,Cytokinetics股价,Cytokinetics股市,Cytokinetics股票价格,Cytokinetics股票交易,Cytokinetics股票购买,Cytokinetics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cytokinetics(CYTK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cytokinetics(CYTK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}